AIMS: To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially significant, prognostic markers. METHODS AND RESULTS: Clinical data and follow-up, histopathological features (pattern, cell size, thickness, mitoses, vascular invasion, lymphocytic infiltration) and immunohistochemical detection [CK20, thyroid transcription factor (TTF-1), chromogranin A, synaptophysin, p53, Ki67, Fli-1, CD99, c-Kit] were evaluated in 20 cases of MCC. Fli-1 and CD99 were detected in 90% and 55% of cases, respectively. Tumour size>30 mm, stage II, 'absent' lymphocytic infiltration, and the presence of>50% of Ki67+ tumour cells, were found to be prognostic indicators of disease-free interval (DFI), but only 'absent' lymphocytic infiltration constituted an independent prognostic factor of DFI after multivariate analysis. For overall survival, the same variables, together with local recurrence and lymph node involvement, had prognostic significance, with only local recurrence as an independent prognostic factor after multivariate analysis. CONCLUSIONS: Absence of lymphocytic infiltration and Ki67 immunoreactivity in more than 50% of tumour cells should be evaluated in conjunction with other well-known prognostic markers in MCC. Furthermore, recognizing that Fli-1 and CD99 expression is commonly found in MCC by immunohistochemistry may avoid misinterpretation in the differential diagnosis of MCC with other small round cell tumours.
AIMS: To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially significant, prognostic markers. METHODS AND RESULTS: Clinical data and follow-up, histopathological features (pattern, cell size, thickness, mitoses, vascular invasion, lymphocytic infiltration) and immunohistochemical detection [CK20, thyroid transcription factor (TTF-1), chromogranin A, synaptophysin, p53, Ki67, Fli-1, CD99, c-Kit] were evaluated in 20 cases of MCC. Fli-1 and CD99 were detected in 90% and 55% of cases, respectively. Tumour size>30 mm, stage II, 'absent' lymphocytic infiltration, and the presence of>50% of Ki67+ tumour cells, were found to be prognostic indicators of disease-free interval (DFI), but only 'absent' lymphocytic infiltration constituted an independent prognostic factor of DFI after multivariate analysis. For overall survival, the same variables, together with local recurrence and lymph node involvement, had prognostic significance, with only local recurrence as an independent prognostic factor after multivariate analysis. CONCLUSIONS: Absence of lymphocytic infiltration and Ki67 immunoreactivity in more than 50% of tumour cells should be evaluated in conjunction with other well-known prognostic markers in MCC. Furthermore, recognizing that Fli-1 and CD99 expression is commonly found in MCC by immunohistochemistry may avoid misinterpretation in the differential diagnosis of MCC with other small round cell tumours.
Authors: A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt Journal: J Cancer Res Clin Oncol Date: 2017-06-21 Impact factor: 4.553
Authors: Samuel A Henderson; Michael T Tetzlaff; Penvadee Pattanaprichakul; Patricia Fox; Carlos A Torres-Cabala; Roland L Bassett; Victor G Prieto; Hunter W Richards; Jonathan L Curry Journal: J Cutan Pathol Date: 2014-10-28 Impact factor: 1.587
Authors: Franz O Smith; Binglin Yue; Suroosh S Marzban; Brooke L Walls; Michael Carr; Ryan S Jackson; Christopher A Puleo; Tapan Padhya; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Michael J Schell; Ronald C DeConti; Jane L Messina; Vernon K Sondak; Jonathan S Zager Journal: Cancer Date: 2015-06-02 Impact factor: 6.860
Authors: Dita Gratzinger; Shuchun Zhao; Robert West; Robert V Rouse; Hannes Vogel; Elena Cubedo Gil; Ronald Levy; Izidore S Lossos; Yasodha Natkunam Journal: Am J Clin Pathol Date: 2009-02 Impact factor: 2.493